Celcuity

Celcuity P/B

The P/B (Price-to-Book Ratio) of Celcuity (CELC) as of Sep 27, 2026 is 51.99. In the previous year, P/B (Price-to-Book Ratio) was 45.22 — a change of 14.98% (higher).

P/B

51.99

YoY

14.98%

Last updated:

P/B (Price-to-Book Ratio) of Celcuity is 2026 51.99 . P/B (Price-to-Book Ratio) of Celcuity was 2025 45.22 . It decreases by 14.98% higher compared to the previous year.

The Celcuity P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2018
206.24 USD
Jan 1, 2019
270.92 USD
Jan 1, 2020
446.77 USD
Jan 1, 2021
76.09 USD
Jan 1, 2022
39.08 USD
Jan 1, 2023
37.41 USD
Jan 1, 2024
45.22 USD
Jan 1, 2025
51.99 USD
The Celcuity P/B history
YEARP/BYoY
51.99+14.98%
45.22+20.89%
37.41-4.29%
39.08-48.64%
76.09-82.97%
446.77+64.90%
270.92+31.36%
206.24+23.83%
166.55-82.12%
931.67-10.61%
1,042.22—
Access this data via the Eulerpool API

Celcuity Stock analysis

What does Celcuity do? Celcuity Inc is a biotechnology company founded by Brian Sullivan in 2012. The company is headquartered in Minneapolis, USA. The business model of Celcuity is based on researching and developing new diagnostic and treatment methods for various types of cancer. The company utilizes a proprietary technology platform called CELx, which enables the analysis of cancer cell signaling pathways and the development of individualized treatment strategies. Celcuity specializes in the development of diagnostics and personalized therapies based on individual cancer cell signaling pathways. The company operates in two divisions: 1. Diagnostics division: Celcuity's diagnostics division focuses on identifying new cancer markers and biomarkers for early detection of cancer and the development of individualized treatment strategies. 2. Therapy division: Celcuity's therapy division specializes in the development of personalized therapies based on individual cancer cell signaling pathways. Celcuity currently offers two products based on the CELx technology platform: 1. CELx HUB: CELx HUB is a cloud-based software that allows doctors and researchers to analyze cancer samples and develop individualized treatment strategies. 2. CELx TIL: CELx TIL is a diagnostic tool that measures the presence of tumor cells in the immune system of cancer patients. In summary, Celcuity Inc is a leader in the field of personalized cancer therapy based on individual cancer cell signaling pathways. The company has found a niche in this growing market and has a unique technology platform that allows it to serve its customers effectively. With its products and services, Celcuity is helping to revolutionize cancer treatment and improve the quality of life for cancer patients worldwide. Celcuity is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Celcuity stock

P/B (Price-to-Book Ratio) of Celcuity is 51.99 in 2026.

P/B (Price-to-Book Ratio) of Celcuity changed from 45.22 to 51.99, representing a 14.98% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Celcuity since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Celcuity with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Celcuity

All Key Metrics — Celcuity